![]() Initiate a Phase 1/2 trial of BLU-222 in cyclin E-CDK2 aberrant cancers in the first quarter of 2022.The company plans to achieve the following milestones by mid-2022: Announced the appointment of Daniella Beckman, Chief Financial Officer of Tango Therapeutics, to the company's Board of Directors.In addition, announced a role expansion for Helen Ho, Ph.D., to Chief Business Officer. Announced promotions for Christina Rossi to Chief Operating Officer and Philina Lee, Ph.D., to Chief Commercial Officer.Haviland will join the Board of Directors. Albers will transition from his current role as Chairman, President and Chief Executive Officer to Executive Chairman of the Board of Directors. Announced Kate Haviland, who has served as Chief Operating Officer and previously Chief Business Officer since 2016, has been appointed by the company's Board of Directors to succeed Jeff Albers as President and Chief Executive Officer, effective April 4, 2022. ![]() Received FDA clearance for an IND application for BLU-222 for cyclin E-CDK2 aberrant cancers.Food and Drug Administration (FDA) for an investigational new drug (IND) application for BLU-451 in EGFR exon 20 insertion-positive NSCLC.īLU-222: ovarian, breast and other cyclin E-CDK2 aberrant cancers Completed the acquisition of Lengo Therapeutics and its lead compound BLU-451, a potential best-in-class precision therapy for EGFR exon 20 insertion-positive NSCLC.Announced a strategic collaboration and license agreement with Zai Lab Limited for the development and commercialization of BLU-945 and BLU-701 for the treatment of EGFR-driven NSCLC in Greater China. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |